GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Phase 1 Completed
13 enrolled
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Phase 1 Completed
9 enrolled
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Phase 1 Terminated
60 enrolled
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase 1 Completed
18 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Phase 1 Terminated
50 enrolled
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase 1 Completed
23 enrolled